» Articles » PMID: 29450753

Use of Breast Imaging After Treatment for Locoregional Breast Cancer (AFT-01)

Overview
Journal Ann Surg Oncol
Publisher Springer
Specialty Oncology
Date 2018 Feb 17
PMID 29450753
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Annual mammography is recommended after breast cancer treatment. However, studies suggest its under-utilization for Medicare patients. Utilization in the broader population is unknown, as is the role of breast magnetic resonance imaging (MRI). Understanding factors associated with imaging use is critical to improvement of adherence to recommendations.

Methods: A random sample of 9835 eligible patients receiving surgery for stages 2 and 3 breast cancer from 2006 to 2007 was selected from the National Cancer Database for primary data collection. Imaging and recurrence data were abstracted from patients 90 days after surgery to 5 years after diagnosis. Factors associated with lack of imaging were assessed using multivariable repeated measures logistic regression with generalized estimating equations. Patients were censored for death, bilateral mastectomy, new cancer, and recurrence.

Results: Of 9835 patients, 9622, 8702, 8021, and 7457 patients were eligible for imaging at surveillance years 1 through 4 respectively. Annual receipt of breast imaging declined from year 1 (69.5%) to year 4 (61.0%), and breast MRI rates decreased from 12.5 to 5.8%. Lack of imaging was associated with age 80 years or older and age younger than 50 years, black race, public or no insurance versus private insurance, greater comorbidity, larger node-positive hormone receptor-negative tumor, excision alone or mastectomy, and no chemotherapy (p < 0.005). Receipt of breast MRI was associated with age younger than 50 years, white race, higher education, private insurance, mastectomy, chemotherapy, care at a teaching/research facility, and MRI 12 months before diagnosis (p < 0.05).

Conclusion: Under-utilization of mammography after breast cancer treatment is associated with sociodemographic and clinical factors, not institutional characteristics. Effective interventions are needed to increase surveillance mammography for at-risk populations. ClinicalTrials.gov Identifier: NCT02171078.

Citing Articles

Surveillance Imaging after Primary Diagnosis of Ductal Carcinoma in Situ.

Byng D, Thomas S, Rushing C, Lynch T, McCarthy A, Francescatti A Radiology. 2023; 307(1):e221210.

PMID: 36625746 PMC: 10068891. DOI: 10.1148/radiol.221210.


Early stage breast cancer follow-up in real-world clinical practice: the added value of cell free circulating tumor DNA.

La Rocca E, De Santis M, Silvestri M, Ortolan E, Valenti M, Folli S J Cancer Res Clin Oncol. 2022; 148(6):1543-1550.

PMID: 35396978 PMC: 9114063. DOI: 10.1007/s00432-022-03990-7.


ASO Author Reflections: Use of Breast Imaging After Treatment for Locoregional Breast Cancer (AFT-01).

Adesoye T, Schumacher J, Greenberg C Ann Surg Oncol. 2018; 26(Suppl 3):553-554.

PMID: 30565039 PMC: 7474977. DOI: 10.1245/s10434-018-7070-9.


'Under' Surveillance: Impact of Race and Socioeconomic Status on Post-Treatment Breast Cancer Imaging.

De La Cruz L, Shulman L Ann Surg Oncol. 2018; 25(6):1456-1457.

PMID: 29516361 PMC: 5928176. DOI: 10.1245/s10434-018-6418-5.

References
1.
Orel S . Who should have breast magnetic resonance imaging evaluation?. J Clin Oncol. 2008; 26(5):703-11. DOI: 10.1200/JCO.2007.14.3594. View

2.
Houssami N, Ciatto S, Martinelli F, Bonardi R, Duffy S . Early detection of second breast cancers improves prognosis in breast cancer survivors. Ann Oncol. 2009; 20(9):1505-1510. DOI: 10.1093/annonc/mdp037. View

3.
Colleoni M, Sun Z, Price K, Karlsson P, Forbes J, Thurlimann B . Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. J Clin Oncol. 2016; 34(9):927-35. PMC: 4933127. DOI: 10.1200/JCO.2015.62.3504. View

4.
Regan M, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L . Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol. 2011; 12(12):1101-8. PMC: 3235950. DOI: 10.1016/S1470-2045(11)70270-4. View

5.
Parmar A, Sheffield K, Vargas G, Han Y, Chao C, Riall T . Quality of post-treatment surveillance of early stage breast cancer in Texas. Surgery. 2013; 154(2):214-25. PMC: 3728715. DOI: 10.1016/j.surg.2013.04.004. View